Showing results (191-200 of 218) with videos related to
Sort By:
Pageof 22
The Lancet. Oncology|March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.International Journal of Dermatology|December 13, 2025
Dermoscopy in Merkel Cell Carcinoma-A Multicenter Retrospective Study of the International Dermoscopy SocietyKatarzyna Korecka, Iulia Maria Badiu, Philipp Tschandl, et al.Journal of the National Cancer Institute|December 20, 2015
PARKIN Inactivation Links Parkinson's Disease to MelanomaHui-Han Hu, Caroline Kannengiesser, Suzanne Lesage, et al.Journal of the American Academy of Dermatology|September 24, 2018
Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy SocietyOriol Yélamos, Cristián Navarrete-Dechent, Michael A Marchetti, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 11, 2024
International Skin Imaging Collaboration-Designated Diagnoses (ISIC-DX): Consensus terminology for lesion diagnostic labelingAlon Scope, Konstantinos Liopyris, Jochen Weber, et al.Journal of the American Academy of Dermatology|July 31, 2012
Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a familyEve Maubec, Valérie Chaudru, Hamida Mohamdi, et al.The Journal of Investigative Dermatology|October 30, 2009
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutationsChristine Bodemer, Olivier Hermine, Fabienne Palmérini, et al.The Lancet. Oncology|June 16, 2019
Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic studyPhilipp Tschandl, Noel Codella, Bengü Nisa Akay, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.Pageof 22